ERBB2 and neoplasm: We found that increased levels of PEAK1 expression correlate with multiple markers of poor patient prognosis, such as metastatic lesions, disease relapse, advanced N stage, tumor grade, HER2 status, and stromal-derived prognostic predictor (SDPP) status (Fig 1A).